Historically, the immune system’s defenses have been categorized into two distinct arms: innate immunity, the body’s first line of defense from birth against a broad range of bacteria and viruses, and adaptive immunity, which tailors long-term defense through specific recognition and memory formation against particular pathogens. Vaccines have conventionally targeted adaptive immunity, instructing lymphocytes to recognize and neutralize invading organisms. Yet, an intriguing exception has been the Bacillus Calmette-Guérin (BCG) vaccine, primarily designed against tuberculosis, which goes beyond stimulating adaptive responses. BCG notably enhances innate immune vigilance, broadly reducing infections from various respiratory pathogens by effectively “training” innate immune cells.

This trained immunity has puzzled scientists for years. How does a vaccine targeting a single bacterium enhance the broader responsiveness of innate immune cells to multiple unrelated pathogens? The answer lies at the intersection of cellular metabolism and epigenetics, the latter referring to the molecular modifications that regulate gene expression without altering the underlying DNA sequence. Recently, an international team led by Mihai Netea at Radboud University Medical Center has elucidated this mechanism with unprecedented depth, revealing how metabolic shifts engender lasting epigenetic changes that underpin trained immunity.

Central to their discovery is lactate, a molecule produced abundantly during heightened glycolytic activity when immune cells ramp up glucose consumption. While lactate had long been relegated to the status of a metabolic byproduct accumulating during anaerobic respiration, emerging evidence indicates it plays a far more sophisticated role. Specifically, lactate can modify histones, the protein complexes around which DNA is wound, through a process called histone lactylation. This epigenetic modification alters chromatin structure, modulating gene accessibility and expression, essentially reprogramming immune cells to a more alert and reactive state.

Using sophisticated molecular assays and immune profiling of BCG-vaccinated healthy volunteers, the researchers observed strong correlations between lactate levels and the production of inflammatory cytokines, signaling molecules that orchestrate immune defense. These findings revealed that lactate-induced histone lactylation persisted in innate immune cells for up to three months post-vaccination, sustaining an enhanced inflammatory response poised to counter new microbial threats. Moreover, pharmacologically disrupting lactate production significantly diminished the trained immunity response, underscoring lactate’s pivotal role as a molecular regulator rather than an inert byproduct.

The implications of these findings resonate beyond the immediate scope of tuberculosis or BCG vaccination. They challenge the dogma of the immune system’s division into rigidly separate innate and adaptive arms, highlighting a nuanced metabolic-epigenetic crosstalk that enables innate immune cells to retain functional memory. This metabolic rewiring encompasses not only enhanced glycolysis and lactate production but also a cascade of epigenetic alterations that recalibrate gene expression landscapes, enabling innate cells to respond more vigorously upon subsequent encounters with diverse pathogens.

Technically, histone lactylation represents a novel layer of epigenetic modification, distinct yet analogous to more classical marks like methylation and acetylation. It involves the covalent attachment of lactyl groups to lysine residues on histones, modulating chromatin configuration and gene transcription patterns. In the context of trained immunity, this process facilitates the upregulation of key inflammatory genes, effectively “bookmarking” regions of the genome for rapid activation. The persistence of these modifications implies that metabolic states can exert long-term influence over immune cell behavior, a concept with profound therapeutic potential.

The research employed cutting-edge technologies including chromatin immunoprecipitation sequencing (ChIP-seq) to map lactylation sites genome-wide and advanced mass spectrometry for precise quantification. These approaches combined to provide a holistic view of how metabolic shifts translate into epigenetic remodeling in human immune cells. Their experimental design included controlled human vaccination trials paired with in vitro manipulation of metabolic pathways, allowing the team to causally link lactate production with trained immunity outcomes.

This metabolic-epigenetic interplay not only sheds light on the mechanisms induced by the BCG vaccine but also opens avenues to enhance vaccine efficacy and design novel immunomodulatory therapies. If lactate can be harnessed or mimicked pharmacologically, it may be possible to fine-tune innate immune responses, offering broad protection against respiratory infections and possibly even cancer and autoimmune diseases where innate immunity plays a critical role.

Importantly, the study highlights the plasticity of the innate immune system and its capacity for durable memory-like properties traditionally ascribed only to adaptive immunity. This paradigm shift deepens our understanding of host defense and emphasizes metabolism as a therapeutic target to modulate immunity. The interplay between sugars, lactate, and epigenetic memory represents a frontier of immunology that marries bioenergetics with genomics, promising a new era of metabolic immunotherapy.

Additionally, the discovery reframes lactate, the long-maligned molecule associated with muscle fatigue and metabolic stress, as an essential signaling mediator finely tuning immune readiness. This redefinition inspires reconsideration of metabolic byproducts in biological regulation and their potential as biomarkers or intervention points in immune-related diseases.

Future research could explore how various metabolic states—such as those induced by diet, exercise, or disease—affect histone lactylation and innate immune memory. Moreover, understanding individual variability in these pathways could guide personalized vaccination strategies and immunotherapies. The interplay between microbiome-derived metabolites and host lactate signaling also represents an unexplored axis with potential relevance for mucosal immunity and systemic inflammation.

In conclusion, the work spearheaded by Netea and colleagues illuminates a crucial link between metabolism and epigenetics in human innate immunity. Lactate emerges not as a passive product but an active instructor shaping immune cell function through epigenetic remodeling. This discovery enriches the conceptual framework of trained immunity and opens transformative possibilities for vaccine science and immunological health interventions.

Subject of Research: People
Article Title: Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory
News Publication Date: 2-May-2025
Web References: http://dx.doi.org/10.1016/j.cell.2025.03.048
References: Ziogas A., Novakovic B., Ventriglia L., et al. Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory. Cell. 2025.
Keywords: Trained immunity, innate immune memory, lactate, histone lactylation, epigenetics, BCG vaccine, metabolism, glycolysis, immune training, cytokine response

Historically, the adaptive immune system has received significant attention for its role in immunological memory, allowing the body to mount tailored responses against previously encountered pathogens. However, the innate immune system was long viewed as a primitive, non-adaptive branch of immunity, lacking the ability to "remember" past threats. Recent investigations over the last decade, however, have begun to dismantle this paradigm, revealing that innate immune responses can indeed be strengthened through previous exposures to various stimuli, akin to the memory function traditionally attributed to the adaptive immune system.

Central to this understanding is the role of certain compounds, like β-glucan, which is derived from fungi and shown to modulate the immune response. In experimental settings, researchers demonstrated that β-glucan induces TRIM, thereby priming osteoclast precursors in the bone marrow to differentiate into osteoclasts more readily. This differentiation process becomes particularly pronounced when an inflammatory challenge, such as arthritis, is introduced, suggesting that this trained immunity contributes to augmented bone resorption.

The implications of these findings are significant, particularly in the context of chronic inflammatory diseases. George Hajishengallis, a lead researcher on the study, emphasizes that while TRIM can confer protective effects against certain infections and tumors, it can concurrently exacerbate inflammatory responses and contribute to disease progress, particularly in conditions associated with bone loss. This duality indicates a complex interplay within the immune system that demands further investigation to truly harness its therapeutic potential.

Research indicates that the memory facilitated by TRIM can manifest in varying outcomes, either beneficial or detrimental depending on context. It has become increasingly clear that inflammatory responses, while naturally protective, can also become pathological when dysregulated. The investigation into TRIM’s role in bone metabolism challenges traditional views and opens avenues for tailored therapeutic strategies aimed at mitigating unwanted inflammatory effects while enhancing the immune system’s protective capabilities.

Furthermore, the findings suggest that it is not merely the initial exposure to a stimulus that determines the outcomes associated with TRIM, but rather the subsequent environmental factors and challenges faced by the immune system. This nuanced understanding shifts the focus from singular stimuli as drivers of immune responses to a broader consideration of the immunological context—highlighting how the innate immune system’s training can lead to increased susceptibility to diseases characterized by inflammatory processes, such as periodontitis and arthritis.

Hajishengallis and his team’s research offers critical insights into the mechanisms underlying TRIM and its effects on osteoclastogenesis, particularly demonstrating how β-glucan can heighten the response of osteoclasts during subsequent inflammatory challenges. While this training effect enhances the capacity of the immune response to deal with infections, it also underscores a risk factor for inflammatory bone loss in susceptible individuals. This reveals a critical paradox where immune training may be a double-edged sword; on one side lies enhanced protective mechanisms, while on the other, heightened reactivity can instigate or worsen existing inflammatory bone disorders.

The importance of these findings extends beyond theoretical discussions and into clinical application. For decades, cancer immunotherapy and vaccine development have predominantly revolved around enhancing the adaptive immune response. Now, the growing recognition of TRIM necessitates a reevaluation of the strategies implemented in treating autoimmune diseases and chronic inflammatory conditions. Harnessing the innate immune system through approaches designed to optimize TRIM could herald a new era in the management of inflammatory diseases, offering a potential pathway for interventions that can restore balance and function to dysregulated immune systems.

Future studies will need to delve deeper into the cellular and molecular mechanisms that define TRIM’s effects. Investigating the pathways linking β-glucan treatment with osteoclast differentiation could unveil novel targets for therapeutic intervention. Moreover, understanding how different stimuli modulate the innate immune response in various contexts may provide valuable insights into preventing or mitigating the adverse effects of chronic inflammation and bone loss.

Ultimately, the work conducted by Hajishengallis and Chavakis positions itself at the forefront of a paradigm shift in immunology. The insights garnered from this research challenge previously accepted doctrines about the innate immune system and point toward future avenues for exploration. As researchers continue to untangle the complexities of TRIM, the therapeutic prospects for patients suffering from inflammatory diseases could be significantly enhanced.

This groundbreaking research, set to be published in Developmental Cell, underscores the need for a comprehensive understanding of the immune system to develop effective therapeutic strategies against a myriad of diseases. As historical barriers between innate and adaptive immunity are dismantled, a new vision for the role of innate immunity in health and disease emerges—one that holds the potential to reshape the landscape of immunological science and clinical practice undeniably.

Subject of Research: Animals
Article Title: Innate immune training of osteoclastogenesis promotes inflammatory bone loss in mice
News Publication Date: 27-Feb-2025
Web References: https://www.dental.upenn.edu/, https://www.sciencedirect.com/science/article/pii/S1534580725000632
References: 10.1016/j.devcel.2025.02.001
Image Credits: Created with BioRender.com by George Hajishengallis and Triantafyllos Chavakis, 2025

Keywords: Innate immunity, osteoclastogenesis, chronic inflammation, inflammatory diseases, immune memory.